Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Endometrial Neoplasms 7 Ovarian Neoplasms 6 Neoplasms 6 Uterine Cervical Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 3 Rectal Neoplasms 3 Pancreatic Neoplasms 3 Neoplasm Metastasis 3 Head and Neck Neoplasms 3 Colonic Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Breast Neoplasms 3 Triple Negative Breast Neoplasms 2 Lung Neoplasms 2 Fallopian Tube Neoplasms 2 Carcinoma, Neuroendocrine 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Turcot syndrome 1 Small Cell Lung Carcinoma 1 Sarcoma, Clear Cell 1 Sarcoma 1 Recurrence 1 Penile Neoplasms 1 Pathologic Complete Response 1 Neoplasms, Second Primary 1 Mesothelioma, Malignant 1 Mesothelioma 1 Melanoma 1 MMRd/MSI-H Stage II-III Endometrial Cancer 1

Interventions

tebentafusp 1 dostarlimab 1 cobimetinib 1 cabozantinib 1 atezolizumab 1 Vemurafenib 1 Specimen Handling 1 Radiation Dose Hypofractionation 1 Diathermy 1 Crizotinib 1 Biopsy 1 ARQ 197 1 AMG 337 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Sarcoma, Clear Cell × dostarlimab × Clear all

NCT04274023 2024-02-01

ACCeSs

Italian Sarcoma Group

Phase 2 Terminated

Sarcoma, Clear Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡